Holocene Advisors’s Coherus Oncology CHRS Stock Holding History

Holocene Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-593,967	Closed	-$10.7M	–	688
2019 Q4	$10.7M	Buy	+593,967	New	+$11M	0.1%	151

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Holocene Advisors's CHRS Position: Q1 2020 in Review

Holocene Advisors sold out of Coherus Oncology (CHRS) in Q1 2020, closing a stake of 593,967 shares — an estimated $10.7M sold.

Holocene Advisors first reported a position in CHRS in Q4 2019 and held it in 1 quarter. The position peaked at $10.7M in Q4 2019. 186 funds tracked by Wall St. Rank hold CHRS as of Q1 2020.

Holocene Advisors reported no remaining Coherus Oncology position as of Q1 2020 after selling out during the quarter.
Holocene Advisors sold 593,967 Coherus Oncology shares in Q1 2020, an estimated $10.7M.
Holocene Advisors first reported a position in Coherus Oncology in Q4 2019 and held it in 1 quarter.
Holocene Advisors's Coherus Oncology position peaked at $10.7M in Q4 2019.
186 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2020.

Based on Holocene Advisors's 13F filing for Q1 2020, filed 15 May 2020.